Statins: The drugs for the 21st century?

Bratislava Medical Journal

Volumn 110, Issue 10, 2009, Pages 664-668

  Ginter, E ^a   Simko, V ^b  

^a INST OF PREV AND CLINICAL MEDICINE   (Slovakia)

^b SUNY DOWNSTATE MEDICAL CENTER   (United States)

Author keywords

Coenzyme Q10; Heart disease; Low density lipoproteins; Myopathy; Side effects; Statins

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

HUMAN; REVIEW;

HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS;

EID: 75649132215     PISSN: 00069248     EISSN: 13360345     Source Type: Journal    
DOI: None     Document Type: Review

References (46)

1. Mann D. Trends in statin use and low-density lipoprotein cholesterol levels among US adults: Impact of the 2001 National Cholesterol Education Program Guidelines. Ann Pharmacother 2008; 42: 1208-1215.
2. Efthimiades A. Rosuvastatin and cardiovascular disease:did the strongest statin hold the initial promises? Angiology 2008; 59: 62S-64S.
3. Rizzo M, Rini GB, Berneis R. Effects of statins, fibrates, rosuvasta tin and ezetimibe beyond cholesterol: the modulation of LDL size and subclasses in high-risk patients. Adv Ther 2007; 24: 575-582.
4. Thavendiranathan P, Bagai A, Brookhart A et al. Primary prevention of cardiovascular diseases with statin therapy. A meta-analysis of randomized controlled trials. Arch Intern Med 2006; 166: 2307-2313.
5. Afilalo J, Majdan AA, Eisenberg MJ. Intensive statin therapy in acute coronary syndromes and stable coronary heart disease: a comparative meta-analysis of randomised controlled trials. Heart 2007; 93: 914-921.
6. Fauchier L, Pierre B, de Labriolle A et al. Antiarrhythmic effect of statin therapy and atrial fibrillation. A Meta-Analysis of randomized controlled trials. J Amer Coll Cardiol 2008; 51: 828-835.
7. O'Regan C, Wu P, Arora P et al. Statin therapy in stroke prevention: A meta-analysis Involving 121,000 patients. Amer J Med 2008; 121: 24-33.
8. Josan K, Majumdar SR, McAlister FA. The efficacy and safety of intensive statin therapy: A meta-analysis of randomized trials CMAJ 2008; 178: 576-584.
9. Sillberg VA, Wells GA, Perry JJ. Do statins improve outcomes and reduce the incidence of vasospasm after aneurysmal subarachnoid he morrhage: A meta-analysis. Stroke 2008; 39: 2622-626.
10. Ebrahimi R, Saleh J, Toggart E et al. Effect of preprocedural myocardial infarction and major cardiac adverse events in percutaneous coronary intervention: A meta-analysis. J Invasive Cardiol 2008; 20: 292-295.
11. Liakopoulos OJ, Choi YH, Haldenwang PL et al. Impact of preo-perative statin therapy on adverse postoperative outcomes in patients undergoing cardiac surgery: A meta-analysis of over 30,000 patients. Eur Heart J 2008; 29: 1548-1559.
12. Aronow WS. Treatment of high-risk older persons with lipid-lowe-ring drug therapy. Amer J Ther 2008; 15: 102-107.
13. Strippoli GF, Navaneethan SD, Johnson DW et al. Effects of statins in patients with chronic kidney disease: meta-analysis and meta-re-gression of randomised controlled trials. Brit Med J 2008; 336: 645-651.
14. Messerli FH, Pinto L, Tang SS et al. Impact of systemic hypertension on the cardiovascular benefits of statin therapy - a meta-analysis. Amer J Cardiol 2008; 101: 319-325.
15. Kearney PM, Blackwell L, Collins R et al. Efficiacy of choleste rol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: A meta-analysis. Lancet 2008; 371: 117-125.
16. Libby P. Atherosclerosis: the new view. Sci Amer 2002; 286: 47-55.
17. Libby P. The molecular mechanisms of the thrombotic complications of atherosclerosis. J Intern Med 2008; 263: 517-527.
18. Ridker PM, Rifai N, Rose L et al. Comparison of C-Reactive Protein and Low-Density Lipoprotein cholesterol levels in the prediction of first cardiovascular events. New Engl J Med 2002; 347: 1557-1565.
19. Ridker PM, Danielson E, Fonseca FA, JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. New Engl J Med 2008;359: 2195-2207.
20. Thomas SR, Witting PK, Drummond GR. Redox control of endo-thelial function and dysfunction: molecular mechanisms and therapeutic opportunities. Antioxid Redox Signal 2008; 10: 1713-1765.
21. Yemisci M, Ay H, Kocaefe C et al. Statin potentiates human plate let eNOS activity without enhancing eNOS mRNA and protein levels. Cerebrovasc Dis 2008; 26: 190-198.
22. Wang CY, Liu PY, Liao JK. Pleiotropic effects of statin therapy: molecular mechanisms and clinical results. Trends Mol Med 2008; 14: 37-44.
23. Liao JK, Laufs U. Pleiotropic effects of statins. Annu Rev Pharma col Toxicol 2005; 45: 89-118.
24. Lahera V, Goicoechea M, Soledad G et al. Endothelial dysfunction, oxidative stress and inflammation in atherosclerosis: beneficial effects of statins. Curr Med Chem 2007; 14: 243-248.
25. Selwyn AP. Antiatherosclerotic effects of statins: LDL versus non-LDL effects. Curr Atheroscler Rep 2007; 9: 281-285.
26. de Ferranti S, Ludwig DS. Storm over Statins - The controversy surrounding pharmacologic treatment of children. New Engl J Med 2008; 359: 1309-1312.
27. Lahera V, Goicoechea M et al.Statin-related adverse events: a meta-analysis. Clin Ther 2006; 28: 26-35.
28. Dale KM, Coleman CI, Henyan NN et al. Statins and cancer risk. A meta-analysis. J Amer Med Ass 2006; 295: 74-80.
29. Kuoppala J, Lamminp̈̈ A, Pukkala E. Statins and cancer: A systematic review and meta-analysis. Eur J Cancer 2008; 44: 2122-2132.
30. Alsheikh-Ali AA, Trikalinos TA, Kent DM et al. Statins, low-density lipoprotein cholesterol, and risk of cancer. J Amer Coll Cardiol 2008; 52: 1141-1147.
31. Hamilton RJ, Goldberg KC, Platz EA et al. The influence of statin medications on prostate-specific antigen levels. J Natl Cancer Inst 2008; 100: 1487-1488.
32. Drazen JM, D'Agostino RB, Ware JH et al. Ezetimibe and Cancer: An uncertain association. New Engl J Med 2008; 359: 1398-1399.
33. Elsayed RK, Evans JD. Emerging lipid-lowering drugs: squalene synthase inhibitors. Expert Opin Emerg Drugs 2008; 13: 309-322.
34. Marcoff L, Thompson PD. The role of coenzyme Q10 in statin-associated myopathy: a systematic review. J Amer Coll Cardiol 2007;49: 2231-2237.
35. Littarru GP, Langsjoen P. Coenzyme Q10 and statins: biochemical and clinical implications. Mitochondrion 2007; 7 (Suppl): S168-174.
36. Mabuchi H, Higashikata T, Kawashiri M et al. Reduction of serum ubiquinol-10 and ubiquinone-10 levels by atorvastatin in hypercho-lesterolemic patients. J Atheroscler Thromb 2005; 12: 111-119.
37. Kawashiri MA, Nohara A, Tada H et al. Comparison of effects of pitavastatin and atorvastatin on plasma coenzyme QIO in heterozygous familial hypercholesterolemia: results from a crossover study. Clin Pharmacol Ther 2008; 83: 731-739.
38. Mabuchi H, Nohara A, Kobayashi J et al. Effects of CoQIO supplementation on plasma lipoprotein lipid, CoQIO and liver and muscle enzyme levels in hypercholesterolemic patients treated with atorvastatin: a randomized double-blind study. Atherosclerosis 2007; 195: 182-189.
39. Chu CS, Kou HS, Lee CJ et al. Effect of atorvastatin withdrawal on circulating coenzyme QIO concentration in patients with hypercholesterolemia. Biofactors 2006; 28: 177-184.
40. Berthold HK, Naini A, Di Mauro S et al. Effect of ezetimibe and/ or simvastatin on coenzyme Q10 levels in plasma: a randomised trial. Drug Saf 2006; 29: 703-712.
41. Molyneux SL, Florkewski SM, George PM et al. Coenzyme Q 10: an independent predictor of mortality in chronic heart failure. J Amer Coll Cardiol 2008; 52: 1435-1441.
42. Chapidze G E, Kapanadze SD, Dolidze NK et al. Combination treatment with coenzyme Q10 and simvastatin in patients with coronary atherosclerosis (Russian). Kardiologiia 2006; 46 (8): 11-13.
43. Caso G, Kelly P, McNurlan MA et al. Effect of coenzyme Q10 on myopathic symptoms in patients treated with statins. Amer J Cardiol 2007; 99: 1409-1412.
44. Molyneux SL, Young JM, Florkowski CM et al. Coenzyme Q10: is there a clinical role and a case for measurement? Clin Biochem Rev 2008; 29: 71-82.
45. Senes M, Erbay AR, Yilmaz FM et al. Coenzyme Q10 and high-sensitivity C-reactive protein in ischemic and idiopathic dilated cardio-myopathy. Clin Chem Lab Med 2008; 46: 382-386.
46. Schaars CF, Stalenkoef AF. Effects of ubiquinone (coenzyme Q 10) onmyopathy in statin users. Curr Opin Lipidol 2008; 19: 553-557.